Suppr超能文献

相似文献

1
Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People.
J Clin Res Pediatr Endocrinol. 2020 Mar 19;12(1):17-28. doi: 10.4274/jcrpe.galenos.2019.2019.0124. Epub 2019 Aug 22.
2
Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.
Curr Med Res Opin. 2019 Mar;35(3):543-552. doi: 10.1080/03007995.2018.1533459. Epub 2018 Nov 9.
3
A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities.
Endocr Res. 2019 Feb-May;44(1-2):46-54. doi: 10.1080/07435800.2018.1513029. Epub 2018 Sep 5.
4
Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.
Orphanet J Rare Dis. 2024 Jul 11;19(1):263. doi: 10.1186/s13023-024-03245-3.
5
Diagnosis and treatment of lipodystrophy: a step-by-step approach.
J Endocrinol Invest. 2019 Jan;42(1):61-73. doi: 10.1007/s40618-018-0887-z. Epub 2018 Apr 27.
6
Metreleptin for metabolic disorders associated with generalized or partial lipodystrophy.
Expert Rev Endocrinol Metab. 2014 May;9(3):205-212. doi: 10.1586/17446651.2014.894877. Epub 2014 Mar 7.
8
Partial lipodystrophy: Clinical presentation and treatment.
Ann Endocrinol (Paris). 2024 Jun;85(3):197-200. doi: 10.1016/j.ando.2024.05.015. Epub 2024 Jun 12.
9
Lipodystrophies in Children.
Horm Res Paediatr. 2022;95(4):305-320. doi: 10.1159/000522620. Epub 2022 Feb 21.
10

引用本文的文献

1
Clinical Guidance for Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment.
Curr Diab Rep. 2025 Sep 2;25(1):47. doi: 10.1007/s11892-025-01603-4.
2
The clinical approach to child and adolescent patients with lipodystrophy: a series of international case discussions.
Front Endocrinol (Lausanne). 2025 Aug 6;16:1597053. doi: 10.3389/fendo.2025.1597053. eCollection 2025.
3
Clinical Management of Dyslipidemia in Infants and Toddlers.
Curr Atheroscler Rep. 2025 Jun 4;27(1):61. doi: 10.1007/s11883-025-01305-y.
5
Assessment of aortomesenteric distance and mesenteric and retroperitoneal adipose tissue thickness in genetic forms of lipodystrophy.
J Endocrinol Invest. 2025 Feb;48(2):445-454. doi: 10.1007/s40618-024-02429-9. Epub 2024 Oct 1.
6
Diagnosis, treatment and management of lipodystrophy: the physician perspective on the patient journey.
Orphanet J Rare Dis. 2024 Jul 11;19(1):263. doi: 10.1186/s13023-024-03245-3.
8
Atypical Diabetes: What Have We Learned and What Does the Future Hold?
Diabetes Care. 2024 May 1;47(5):770-781. doi: 10.2337/dci23-0038.
9
A new mutation in the gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature.
Front Endocrinol (Lausanne). 2023 Jul 12;14:1212729. doi: 10.3389/fendo.2023.1212729. eCollection 2023.
10
Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the Gene: Results From the First-year.
J Clin Res Pediatr Endocrinol. 2023 Aug 23;15(3):329-333. doi: 10.4274/jcrpe.galenos.2022.2022-1-25. Epub 2022 Jun 23.

本文引用的文献

2
Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma.
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3245-3248. doi: 10.1210/jc.2018-02221.
4
Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy.
PLoS One. 2018 Jun 8;13(6):e0199052. doi: 10.1371/journal.pone.0199052. eCollection 2018.
5
Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
J Clin Invest. 2018 Aug 1;128(8):3504-3516. doi: 10.1172/JCI95476. Epub 2018 Jul 16.
6
Renal complications of lipodystrophy: A closer look at the natural history of kidney disease.
Clin Endocrinol (Oxf). 2018 Jul;89(1):65-75. doi: 10.1111/cen.13732. Epub 2018 May 17.
7
Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
Endocrine. 2018 Jun;60(3):479-489. doi: 10.1007/s12020-018-1589-1. Epub 2018 Apr 12.
8
A Novel Generalized Lipodystrophy-Associated Progeroid Syndrome Due to Recurrent Heterozygous LMNA p.T10I Mutation.
J Clin Endocrinol Metab. 2018 Mar 1;103(3):1005-1014. doi: 10.1210/jc.2017-02078.
9
Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges.
Diabetes Metab Syndr Obes. 2017 Sep 13;10:375-383. doi: 10.2147/DMSO.S130810. eCollection 2017.
10
High prevalence of Berardinelli-Seip Congenital Lipodystrophy in Rio Grande do Norte State, Northeast Brazil.
Diabetol Metab Syndr. 2017 Oct 13;9:80. doi: 10.1186/s13098-017-0280-7. eCollection 2017.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验